"People who are squeamish about needles will soon have an alternative, as the Food and Drug Administration has approved a pill version of Wegovy that could be available as soon as next month. Novo Nordisk, maker of the GLP-1 weight-loss drug, announced on Monday that it has received FDA approval for its once-daily pill that has been shown to achieve comparable weight-loss results as the injectable Wegovy."
""As the first oral GLP-1 treatment for people living with overweight or obesity, the Wegovy pill provides patients with a new, convenient treatment option that can help patients start or continue their weight loss journey," Mike Doustdar, president and CEO of Novo Nordisk, said in a statement. "We are very excited for what this will mean for patients in the U.S.""
"The race to get a weight-loss pill on the market has been a long time coming, as Novo Nordisk began clinical trials of the Wegovy pill more than two years ago. Eli Lilly, maker of Zepbound and Mounjaro, is currently testing a weight-loss pill called orforglipron in clinical trials and the drug is part of an FDA priority voucher program that comes with a faster timeframe for reviewing medications. Wegovy is also part of that program."
FDA approved a pill version of Wegovy, a once-daily oral GLP-1 medication shown to achieve weight-loss results comparable to injectable Wegovy. Novo Nordisk said the 25-milligram pill could launch in the United States in early January while awaiting approvals elsewhere. The Wegovy pill uses a higher oral semaglutide dose than the 14-milligram diabetes pill Rybelsus. No pill version of Ozempic is available yet. Novo Nordisk called the Wegovy pill the first oral GLP-1 treatment for people with overweight or obesity and a convenient treatment option. The drug will require a prescription. Eli Lilly is testing an oral candidate under expedited review. About one in eight American adults were taking GLP-1 drugs, especially middle-aged adults.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]